Drug major Sun Pharmaceutical Industries Monday said it has agreed to acquire 18.75 per cent shares of Israel-based Tarsius Pharma for a cash consideration of USD 3 million (over Rs 21 crore).
One of the company’s wholly-owned subsidiaries has agreed to acquire 3,45,622 ordinary shares of Tarsius Pharma, of nominal value of NIS 0.01 each by way of subscription, representing 18.75 per cent of shares of Tarsius on a fully diluted basis, Sun Pharma said in a filing to BSE.
“Cost of acquisition is USD 3 million,” it added.
Indicative time period for completion of the acquisition is before September 15, 2018, Sun Pharma said.
Tarsius is an early stage research and development company focusing on development of drug candidates in the field of ophthalmology, it added.
Shares of Sun Pharmaceutical Industries closed at Rs 639.50 per scrip on BSE, down 3.72 per cent from its previous close.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.